Publications by authors named "H Mitani"
Background: In a randomized phase II/III trial (JCOG1008), weekly cisplatin (40 mg/m) was non-inferior to 3-weekly cisplatin (100 mg/m) for postoperative high-risk head and neck cancer. We investigated how acute kidney injury (AKI), a major dose-limiting toxicity effect of cisplatin, affects overall survival (OS).
Methods: We analyzed 251 patients from JCOG1008 receiving chemoradiotherapy.
Article Synopsis
- A study examined the clinical outcomes of patients with blunt splenic injuries who received transarterial embolization (TAE), focusing on their hemodynamic status (stable vs unstable).
- The research analyzed data from 38 adult patients treated at two centers from 2011 to 2022, comparing the survival rates, rebleeding incidents, and need for splenectomy between hemodynamically stable (HDS) and unstable (HDU) groups.
- Results showed a high survival discharge rate for both groups (88.2% in HDU and 100% in HDS), but highlighted the need for more studies to assess the effectiveness of TAE compared to traditional surgery for HDU patients.
Article Synopsis
- Hypothyroidism is a common late side effect following radiotherapy for head and neck cancer, which the JCOG1008 trial aimed to investigate by analyzing patient data.
- The trial enrolled 261 patients from 28 institutions between 2012 and 2018 and conducted thyroid function tests to identify factors associated with developing hypothyroidism post-treatment.
- Results showed that 16.7% of patients developed hypothyroidism within 2 years, with significant factors being the use of weekly cisplatin and lower baseline free thyroxine levels in those undergoing intensity-modulated radiotherapy.
Objective: Although adverse childhood experiences (ACEs) are associated with poor health in adulthood, positive childhood experiences (PCEs) can reduce the risk of negative health outcomes. This study aimed to investigate whether PCEs in the community (CPCEs, ie, trusted adults other than parents, supportive friends, belongingness to school, or community traditions) would have an independent effect on better health outcomes and moderate the association between ACEs and adult illnesses.
Design: Cross-sectional survey.
Objectives: Acute kidney injury (AKI) represents a major toxicity associated with cisplatin. We developed a risk prediction model for cisplatin-induced AKI in patients with postoperative high-risk head and neck cancer who received chemoradiotherapy during a randomized phase II/III trial, JCOG1008.
Materials And Methods: Two hundred and fifty-one patients received radiotherapy with weekly cisplatin at 40 mg/m (weekly arm) or 3-weekly cisplatin at 100 mg/m (3-weekly arm).